Response to “Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban”
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- July 2011
has subject area
- 1115 Pharmacology and Pharmaceutical Sciences (FoR)
- Anticoagulants (MeSH)
- Factor Xa Inhibitors (MeSH)
- Humans (MeSH)
- Morpholines (MeSH)
- Pharmacology & Pharmacy (Science Metrix)
- Thiophenes (MeSH)
- Thromboembolism (MeSH)
published in
- Journal of Clinical Pharmacology Journal